Could a single cell treatment free liver transplant patients from lifelong drugs?

NCT ID NCT05234190

Ongoing Disease control Sponsor: Quell Therapeutics Limited Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a personalized cell therapy called QEL-001 in 33 liver transplant recipients. The therapy uses a patient's own cells, modified to train the immune system to accept the donated liver. The goal is to see if it is safe and allows patients to stop taking anti-rejection medications without their body rejecting the liver.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder liver failure Rejection, Psychology transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER DISEASES LIVER FAILURE REJECTION; TRANSPLANT, LIVER

Contacts and locations

Locations

Cambridge University Hospitals NHS Foundation Trust

Cambridge, CB2 0QQ, United Kingdom
G. Gergorio Maranon

Madrid, Spain
H. Clinic Barcelona

Barcelona, Spain
H. Saint Luc

Brussels, Belgium
Hopital Erasme

Brussels, Belgium
Hospital Reina Sofia

Córdoba, Spain
King's College Hospital NHS Foundation Trust

London, SE5 9RS, United Kingdom
Queen Elizabeth Hospital

Birmingham, United Kingdom
Royal Free London NHS Foundation Trust

London, NW3 2QG, United Kingdom
UZ Leuven

Leuven, 3000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.